Adial Pharmaceuticals (ADIL) Invested Capital (2018 - 2022)
Adial Pharmaceuticals (ADIL) posted Invested Capital of $232838.0 for Q2 2022, down 5.02% sequentially from $245148.0 in Q1 2022.
Adial Pharmaceuticals (ADIL) Invested Capital (2018 - 2022) Analysis & Trends
Adial Pharmaceuticals has reported Invested Capital for 3 years, with the latest figure at $232838.0 in Q2 2022.
- Quarterly Invested Capital changed N/A year-over-year to $232838.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $232838.0 (down 53.63% YoY) and the FY2021 annual result came in at $256960.0, changed N/A from the prior year.
- Invested Capital retreated to $232838.0 in Q2 2022 per ADIL's latest filing, from $245148.0 in the prior quarter.
- Over five years, Invested Capital peaked at $256960.0 in Q4 2021 and troughed at $28676.0 in Q2 2018.
- A 3-year average of $180445.0 and a median of $232838.0 in 2022 frame the typical range for Invested Capital.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 232,838.00 |
| Mar 31, 2022 | 245,148.00 |
| Dec 31, 2021 | 256,960.00 |
| Sep 30, 2018 | 138,603.00 |
| Jun 30, 2018 | 28,676.00 |